文献速递心力衰竭与心肌病肺血管病与心包/心肌炎

射血分数保留的心力衰竭中肺动脉高压的临床意义与病理生理:美国心脏协会科学咨询

Elucidating the Clinical Implications and Pathophysiology of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Call to Action: A Science Advisory From the American Heart Association.
PubMed 文献 · Circulation · 2022-07-11

该科学咨询聚焦射血分数保留的心力衰竭(HFpEF)患者中肺动脉高压的流行病学、病理生理和治疗需求。此临床表型常见、与不良结局强相关且缺乏循证治疗,咨询旨在阐明知识缺口并提出可操作的研究方向。

要点

  • HFpEF相关肺动脉高压常见且与不良结局强相关
  • 该领域缺乏循证治疗,需精确疾病定义和血流动力学解读
  • 建议投资于非心脏因素、动物模型和分子研究及精准医学试验设计

核心结论

  • HFpEF中肺动脉高压是常见且与不良结局强相关、但缺乏循证治疗的临床表型,需明确知识缺口并优先研究。

研究设计与样本

  • 美国心脏协会科学咨询,基于专家共识总结知识缺口并提出研究优先方向,未报告系统检索方法或样本量。

主要发现

  • 需额外研究的领域包括更精细的疾病定义和血流动力学解读、非心脏因素对肺动脉高压风险的贡献、优化的动物模型以及混合性毛细血管前和毛细血管后肺动脉高压患者的分子研究。

临床怎么用

  • 强调转化研究以揭示病理生理和新治疗靶点,并讨论精准医学、新试验设计和器械治疗等未来治疗前景。

局限性

  • 作为科学咨询,未报告原始研究数据或系统评价,结论基于专家共识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This science advisory focuses on the need to better understand the epidemiology, pathophysiology, and treatment of pulmonary hypertension in patients with heart failure with preserved ejection fraction. This clinical phenotype is important because it is common, is strongly associated with adverse outcomes, and lacks evidence-based therapies. Our goal is to clarify key knowledge gaps in pulmonary hypertension attributable to heart failure with preserved ejection fraction and to suggest specific, actionable scientific directions for addressing such gaps. Areas in need of additional investigation include refined disease definitions and interpretation of hemodynamics, as well as greater insights into noncardiac contributors to pulmonary hypertension risk, optimized animal models, and further molecular studies in patients with combined precapillary and postcapillary pulmonary hypertension. We highlight translational approaches that may provide important biological insight into pathophysiology and reveal new therapeutic targets. Last, we discuss the current and future landscape of potential therapies for patients with heart failure with preserved ejection fraction and pulmonary vascular dysfunction, including considerations of precision medicine, novel trial design, and device-based therapies, among other considerations. This science advisory provides a synthesis of important knowledge gaps, culminating in a collection of specific research priorities that we argue warrant investment from the scientific community.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Brittain EL, Thenappan T, Huston JH, et al. Elucidating the Clinical Implications and Pathophysiology of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Call to Action: A Science Advisory From the American Heart Association. Circulation. 2022. PMID: 35862198. doi:10.1161/CIR.0000000000001079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。